442 material Form 8-K filings that 386 companies we cover made with the SEC in March 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ADMA Biologics reported full-year 2024 total revenue of $426.5 million, up 65% from 2023, and GAAP net income of $197.7 million, which includes an $84.3 million valuation allowance tax benefit. It raised its FY 2025 and 2026 revenue, Adjusted Net Income and Adjusted EBITDA guidance, but said it expects to file its Form 10-K late, on or before March 18, 2025, because KPMG has not yet completed its audit procedures.
FY 2024 revenue $426.5 million vs. $258.2 million in FY 2023; GAAP net income $197.7 million vs. a net loss of $28.2 million
FY 2024 Adjusted EBITDA $164.6 million and Adjusted Net Income $119.2 million, vs. $40.2 million and $0.7 million in FY 2023
FY 2025 total revenue guidance raised to more than $490 million; FY 2026 to more than $605 million
Company intends to file a Form 12b-25 and expects to file the Form 10-K on or before March 18, 2025; KPMG has not completed its audit procedures
Greif reported fiscal first-quarter 2025 results for the quarter ended January 31, 2025. Net sales rose to $1,265.8 million from $1,205.8 million, but net income attributable to Greif fell to $8.6 million from $67.2 million, mainly because the prior-year quarter included a non-recurring $48.1 million income tax benefit. The company also issued low-end fiscal 2025 guidance for Adjusted EBITDA of $710 million and adjusted free cash flow of $245 million.
Net sales $1,265.8 million vs. $1,205.8 million; net income attributable to Greif $8.6 million, or $0.15 per diluted Class A share, vs. $1.17 a year earlier
Adjusted EBITDA $145.1 million, up 5.9%; adjusted free cash flow was a use of $61.9 million
Total debt rose $548.4 million to $2,840.2 million, mainly from the Ipackchem acquisition; leverage ratio 3.63x vs. 2.46x
Plans to divest about 176,000 acres of Southeastern U.S. timberland, with proceeds applied to debt reduction; fiscal 2025 low-end Adjusted EBITDA guidance of $710 million
Kroger said Chairman and CEO Rodney McMullen resigned effective immediately after a Board investigation into his personal conduct, which the company says is unrelated to its financial performance, operations or reporting. Lead Director Ronald Sargent became interim CEO and Chairman, and the company said full-year Identical Sales without fuel are expected at the high end of guidance and Adjusted EPS slightly above the high end of guidance. Shareholders will get full 2024 results and 2025 guidance on March 6, 2025.
Rodney McMullen resigned as Chairman and CEO effective immediately; he forfeits unvested equity awards and will not receive a 2024 bonus.
Ronald Sargent, a director since 2006 and Lead Director since 2017, is interim CEO and Chairman; a Search Committee is seeking a permanent CEO.
Mark Sutton was appointed Lead Director.
Full-year Identical Sales without fuel expected at the high end of guidance; Adjusted EPS expected slightly above the high end of guidance.
N-able reported fourth-quarter 2024 total revenue of $116.5 million, up 7.5% year over year, and said this exceeded its fourth-quarter revenue guidance. GAAP net income for the quarter was $3.3 million, or $0.02 per diluted share, compared with $9.35 million a year earlier. For 2025, the company expects total revenue of $486.5 million to $492.5 million, growth of about 4% to 6% after 10.5% growth in 2024, which signals a slowdown for shareholders.
Q4 2024 revenue $116.5 million, up 7.5%; GAAP net income $3.3 million ($0.02 per diluted share) versus $9.35 million in Q4 2023
Full-year 2024 revenue $466.1 million, up 10.5%; GAAP net income $31.0 million ($0.16 per diluted share)
2025 outlook: total revenue $486.5 million to $492.5 million; adjusted EBITDA $132.0 million to $138.0 million; total ARR $514.0 million to $522.0 million
Q1 2025 outlook: revenue $115.0 million to $116.0 million, about 1% to 2% year-over-year growth
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.